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Neuronal developmentCalmyrin1 (CaMy1) is an EF-hand Ca2+-binding protein expressed in several cell types, including brain neurons.
Using ayeast two-hybrid screenof a human fetal brain cDNA library,we identiﬁedSCG10protein (stathmin2)as a
CaMy1 partner. SCG10 is a microtubule-destabilizing factor involved in neuronal growth during brain
development. We found increased mRNA and protein levels of CaMy1 during neuronal development, which
paralleled the changes in SCG10 levels. In developing primary rat hippocampal neurons in culture, CaMy1 and
SCG10 colocalized in cell soma, neurites, and growth cones. Pull-down, coimmunoprecipitation, and proximity
ligation assays demonstrated that the interaction between CaMy1 and SCG10 is direct and Ca2+-dependent in
vivo and requires the C-terminal domain of CaMy1 (residues 99–192) and the N-terminal domain of SCG10
(residues 1–35). CaMy1didnot interactwith stathmin1, a protein that ishomologouswithSCG10but lacks theN-
terminal domain characteristic of SCG10. CaMy1 interfered with SCG10 inhibitory activity in a microtubule
polymerization assay. Moreover, CaMy1 overexpression inhibited SCG10-mediated neurite outgrowth in nerve
growth factor (NGF)-stimulated PC12 cells. This CaMy1 activity did not occur when an N-terminally truncated
SCG10 mutant unable to interact with CaMy1 was expressed. Altogether, these data suggest that CaMy1 via
SCG10 couples Ca2+ signals with the dynamics of microtubules during neuronal outgrowth in the developing
brain. This article is part of a Special Issue entitled: 11th European Symposium on Calcium.activation domain; ANOVA,
almyrin1; CIB1, calcium and
MEM, Dulbecco's Modiﬁed
n ﬂuorescent protein; GST,
alactopyranoside; MBP, malt-
otein; NCS, neuronal calcium
cetic acid agarose resin; PAX3,
R, polymerase chain reaction;
CG10, superior cervical ganglia
sulfate-polyacrylamide gel
1th European Symposium on
ation, International Institute of
Poland. Tel.: +48 22 5970 760;
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Ca2+ ions play a role as a second messenger in the control of
multiple generic and cell type-speciﬁc processes. In neurons, the list of
Ca2+-regulated processes is particularly rich and includes neuronal
development, growth, and motility [1,2]. Ca2+ signals in the form of
increased intracellular Ca2+ concentration are sensed and transmitted
to cellular effectors by Ca2+-binding proteins, most of which belong tothe EF-hand superfamily [3,4]. These proteins coordinate Ca2+ in the
helix–loop–helix motifs, referred to as EF-hands, and transduce Ca2+
signals by their Ca2+-dependent interactions with protein effectors.
EF-hand Ca2+-signaling proteins in neurons comprise ubiquitous
calmodulin, Ser/Thr phosphatase calcineurin B, a group of S100
proteins, and a subfamily of neuronal calcium sensors (NCS) [4–6].
Calmyrin1 (CaMy1) is a protein member of the novel EF-hand
calmyrin subfamily. Genes encoding calmyrins were identiﬁed from
invertebrates tohumanbygenomic researchandstructural comparisons
[7]. The nucleotide sequences of the mouse or rat and human CaMy1
gene show greater than 93% identity. CaMy1 shares the highest level of
sequence similarity with phosphatase calcineurin B (57%) and the NCS
proteins [8]. Furthermore, basic structural features of CaMy1 resemble
mostly NCS proteins. Similar to NCSs, CaMy1 is N-terminally myristoy-
lated and can associate with membranes. The protein contains four EF-
hand motifs (EF-1 to EF-4), among which EF-3 and EF-4 are functional
andbindCa2+withhighafﬁnity (1.9 μMand0.54 μM, respectively) [7,9].
TheCaMy1 transcript andproteinwere detected in blood cells, heart,
liver, testis, and brain [8,10–12]. CaMy1 protein was ﬁrst identiﬁed in
human platelets as a binding partner and endogenous inhibitor for the
cytoplasmic tail of the integrin αIIb. Its regulatory role in platelet
aggregation was subsequently demonstrated [8,13]. Accordingly,
CaMy1 is also known as calcium and integrin binding protein 1
(CIB1). Biochemical methods also showed that CaMy1 is a ligand of
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[10]. Other CaMy1-interacting proteins were detected in different
tissues [14–16].
We recently described the constitutive expression of CaMy1 in
mature, differentiated neurons in human and rat brains [17,18]. In
normal human brain, CaMy1 was present in a subset of neurons in
several brain regions, including the cortex and hippocampus.Moreover,
the CaMy1 transcript was found in fetal mouse brain [19]. Based on
CaMy1 interactionswith next to BRCA1 gene 1 protein (NBR1; a protein
that plays a putative role in brain development [20]) and paired box 3
protein (PAX3; a transcription factor found in neural crest-derived cell
types and involved in neurogenesis of ophthalmic trigeminal placode
[21–23]), CaMy1 was suggested to be involved in embryogenesis and
neural development.
To learn more about CaMy1 function in neurons and possibly in
human brain development, we searched for CaMy1 protein ligands by
screening a fetal human brain cDNA library in the yeast two-hybrid
system, with CaMy1 as bait. We identiﬁed a direct interaction between
CaMy1 and its novel putative neuronal binding partner, superior
cervical ganglia neural speciﬁc 10 (SCG10), which is also known as
stathmin2. SCG10 is a generic neuronal marker and stathmin family
member and plays a critical role in brain development. Although SCG10
levels in the adult brain are low, high levels of SCG10 expression are
observed in developing central nervous system neurons during the
period of neurite extension and regenerating neurons of the adult brain
[24–29]. SCG10 is considered to function as a key regulator of neurite
outgrowth throughmicrotubule (MT)-destabilizing activity in neuronal
growth cones, which are the motile structures at the tips of advancing
axons and dendrites [30–32]. Neurite elongation and branching and
growth cone extension are accomplished by continuous reorganization
of cytoskeletal proteins, of which MTs are important components.
Microtubule ends in growth cones are constantly extendedor shortened
by polymerization and depolymerization of the α- and β-tubulin
heterodimeric subunits [33]. SCG10 promotes dynamic instability of
MTs by sequestering αβ-tubulin heterodimers, thereby decreasing the
rate of polymerization and increasing the “catastrophe frequency”
reaction and depolymerizing MTs [30]. The regulatory role of SCG10 in
neurite outgrowth was directly demonstrated in PC12 cells stimulated
with NGF [34,35].
Growth cones respond to a wide range of cues that modify
neuronal growth rate and direction [36]. Ca2+ signals have profound
global and local regulatory effects on neural motility and growth cone
guidance that underlie the developmental elongation of neurites. The
effects of Ca2+ signals in growth cones range from neurite outgrowth
to retraction or collapse related to localization and various parameters
of Ca2+ signals [36–38]. Ca2+ signals are known to be transmitted to
cytoskeletal elements in growth cones, but the precise mechanisms
that underlie the different Ca2+ effects on microtubule dynamics
remain largely unknown.
In the present work we aimed at veriﬁcation of the hypothesis that
CaMy1 can functionally transmit Ca2+ signals to SCG10 and regulate
the dynamics of MTs in growing neurons.
2. Materials and methods
2.1. Yeast two-hybrid screen
Vectors, yeast strains, and fetal human brain cDNA were used
according to the library manufacturer's instructions (MATCHMAKER
GAL4 Two-Hybrid System 3, Clontech). Full-length CaMy1 cDNA was
fused in-frame to the GAL4 DNA-binding domain (BD) in the “bait”
vector pGBKT7 and transformed into the AH-109 yeast strain.
Transformants were mated with a Y187 yeast strain carrying a
human fetal cDNA library fusedwith the GAL4 activation domain (AD)
in the pACT2 vector. Approximately 6×106 diploids were screened by
plating on a medium lacking leucine, tryptophan, and histidine andsupplemented with 3-amino-1,2,4-triazole (3-AT, Sigma). Their β-
galactosidase activity was assayed by an X-gal Filter-Lift Assay.2.2. Bacterial and mammalian expression plasmids
Bacterial expression plasmids encoding full-length SCG10 and an
N-terminally truncated mutant (amino acid residues 35–179,
SCG10d35) were constructed by ampliﬁcation of the SCG10 coding
sequence using standard polymerase chain reaction (PCR) with a
template DNA of the positive clone identiﬁed in the yeast two-hybrid
screen. Ampliﬁed fragments were cloned into a pMAL2cx vector (New
England Biolabs). For the expression of the Flag-tagged SCG10 and
SCG10d35 in mammalian cells, SCG10 and oligonucleotides encoding
amino acids 35–179 of SCG10 were cloned into a p3xfFlag CMV14
vector (Sigma). SCG10 cDNA was subcloned into pEGFPN1 vectors
(Clontech).
His-CaMy1 in a pET28a vector was prepared as previously
described [17]. The CaMy1 N-terminal sequence (amino acid residues
1–98, CaMy1NTF), C-terminal sequence (residues 99–192, CaMy1CTF),
and middle sequence (residues 36–146, CaMy1MDF) were PCR-
ampliﬁed and cloned into pGEX4T1 plasmid (Amersham Biosciences)
in-frame with a sequence for glutathione S-transferase (GST). The
eucaryotic expression vector pEGFPN2CaMy1 was prepared as
described previously [18]. For the expression of Flag-tagged CaMy1
in mammalian cells, the CaMy1 sequence was ampliﬁed using
standard PCR and cloned in-frame into p3xFlag CMV14 (Sigma).2.3. Protein expression and puriﬁcation
CaMy1 fused to 6xHis-tag (CaMy1-His) protein was expressed and
puriﬁed from the E. coli BL-21 Rosetta strain (Novagen) as described
previously [17]. Brieﬂy, CaMy1 from a bacterial lysate was ﬁrst pulled
out on Ni2+-nitriloacetic acid agarose resin (Ni-NTA agarose, Qiagen)
according to the manufacturer's protocol. The His-tag was removed
on the column by cleavage with thrombin, and CaMy1 protein was
then puriﬁed to homogeneity on the anion-exchanger MonoQ (FPLC,
Pharmacia).
The CaMy1 fragments CaMy1NTF, CaMy1MDF, and CaMy1CTF fused to
GST were similarly expressed in the E. coli BL-21 DL3 strain. Upon
induction with 0.4 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG,
Sigma), thepeptideswerepuriﬁed frombacterial lysate on a glutathione
Sepharose column according to the manufacturer's protocol (Amer-
sham). The puriﬁed CaMy1 fragments were additionally identiﬁed by
sodiumdodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
followed by immunoblotting with anti-CaMy1 antibodies.
The proteins SCG10-maltose-binding protein (SCG10-MBP), N-
truncated mutant SCG10d35N-MBP, and MBP-tag were expressed in
the E. coliBL21DE3 strain.After 3 h inductionwith 0.4 mM IPTG, bacteria
were harvested by centrifugation and resuspended in 50 mM Tris–HCl,
pH 7.5, 200 mM NaCl, 1 mM EGTA, and 1 mM DTT with Complete™
protease inhibitor cocktail (Roche). Fusion proteins were then puriﬁed
from bacterial lysates on Amylo-Sepharose resin (New England Biolabs)
according to the manufacturer's protocol.2.4. Antibodies
Anti-CaMy1 polyclonal antibodies were obtained as previously
described [18], afﬁnity-puriﬁed over recombinant CaMy1, and
checked for their speciﬁcity by immunoblotting with recombinant
CaMy1 protein and in the extracts of cells transfected with CaMy1. No
cross-speciﬁcity was detected, and these antibodies were used in the
subsequent experiments. The remaining antibodies were purchased
commercially as described below.
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Primary hippocampal cultures were prepared from embryonic day
19 (E19) rat brains and cultured according to procedures described
previously [39,40]. Brieﬂy, hippocampal or cortical neurons were
grown on coverslips coated with poly-L-lysine (30 μg/ml) and laminin
(2 μg/ml) in Neurobasal medium supplemented with B27, 0.5 mM
glutamine, 12.5 mM glutamate, and a penicillin/streptomycin mix-
ture. At 6–9 days in vitro (DIV), hippocampal neurons were trans-
fected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer's protocol and cultured for the next 1–3 days. For the
real-time experiment and Western blot analysis, cortical neurons
were cultured for the indicated time periods, collected in phosphate-
buffered saline (PBS), and processed for further analysis.
HEK293 cells were cultured in Dulbecco's Modiﬁed Eagle Medium
(DMEM, Gibco BRL) supplemented with 4.5 g glucose, 10% fetal bovine
serum (FBS), 1% penicillin/streptomycin mixture, and 2% L-glutamine.
Eighty-percent conﬂuent cells were transiently transfected using
Polyfect reagent (Qiagen) mixed with eukaryotic expression plasmids.
Twenty-four hours post-transfection, cells were washed with ice-cold
PBS, lysed for 1 h at 4 °C in buffer A containing either 2 mM EGTA or
0.2 mM CaCl2, and centrifuged. The resulting supernatant was used in
the protein–protein interaction studies by co-immunoprecipitation.
Human lymphocytes, transformed with Epstein Barr virus, were
maintained in RPMI supplemented with 10% FBS, 1% penicillin/
streptomycin mixture, and 2% L-glutamine. For the pull-down experi-
ments, cellswere collected in PBS and further processed for theprotein–
protein interaction studies.
HeLa cells were maintained in MEM (Sigma) supplemented with
10% FBS, 1% penicillin/streptomycin mixture, and 2% L-glutamine.
Eighty-percent conﬂuent cells were transiently transfected using
Polyfect reagent (Qiagen) mixed with eukaryotic expression plas-
mids. Twenty-four hours post-transfection, cells were ﬁxed for the
immunolocalization experiments and proximity ligation assays.
PC12 cells were cultured on collagen-coated dishes in F12Kmedium
(Gibco BRL) supplemented with 15% horse serum, 2.5% FBS, and 1%
penicillin/streptomycin solution (Sigma). For the differentiation studies,
PC12 cellswereplated on coverslips coatedwithpoly-L-lysine (10 μg/ml,
Sigma) and transfected using Lipofectamine 2000 according to the
manufacturer's protocol. Cellswere further stimulated for differentiation
for 2–5 days with 75 ng/ml human NGF (Invitrogen) dissolved in
low serum medium (F12K supplemented with 1% horse serum and 1%
penicillin/streptomycin solution). Cells were then ﬁxed with 4%
paraformaldehyde (PFA) supplemented with 4% sucrose.
2.6. Reverse-transcription PCR and real-time PCR
Total RNA from cultured primary cortical neurons was isolated with
the RNeasy Plus Mini Kit (Qiagen). The mRNA concentration was
veriﬁed by spectrophotometry, and cDNA was synthesized with the
High Capacity cDNA Reverse Transcription Kit (Applied Biosystems).
Real-time PCR was performed using SYBR-Green dye (Applied Biosys-
tems) and Applied Biosystems hardware and software (7500 RT PCR
System). The following primers were used: CaMy1 (forward TTTGAG-
CAGATCCTCAGCCTTCCA, reverse TGCGGAAGGCATAGTGTGACTTGA),
SCG10 (forward TTCTCGTGGAGTGTGTGCTTCACT, reverse
TAGCTTTGTGTTTGTGTTCGGCCC), doublecortin (forwardATGTCAATCC-
CAACTGGTCGGTCA, reverse TGTTCTCTCTGGCTTGAGCACTGT), and 18S
(forward AACGAACGAGACTCTGGCATG, reverse CGGACATCTAAGGG-
CATCACA). The results were analyzed by the absolute quantiﬁcation
method with a relative standard curve and related to 18S.
2.7. Pull-down assays
For the MBP pull-down experiments, the puriﬁed proteins MBP,
SCG10-MBP, and SCG10d35-MBP were coupled to Amylosepharosebeads (New England Biolabs) according to the manufacturer's
instructions. The resins were equilibrated, and the pull-down assays
were performed in buffer A containing 50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 0.75% CHAPS, 1 mM DTT, and 2 mM EGTA or 0.2 mM
CaCl2. MBP pull-down resins were incubated overnight at 4 °C with
either 5 μg of puriﬁed recombinant proteins (full-length untagged
CaMy1, GST, CaMy1NTF-GST, and CaMy1CTF-GST) or 500 μg protein
of cell lysate supernatants. The cell lysates were prepared as described
in the Co-immunoprecipitation section below from human lympho-
cytes expressing endogenous CaMy1. Unbound fractions were
separated by centrifugation. The resins were extensively washed,
and bound proteins were eluted by adding SDS-PAGE sample buffer to
the resins and boiling at 95 °C for 3 min. Fractions were separated on
12% SDS gel, transferred to a nitrocellulose membrane (ProtranTM,
Whatmann), and subjected to immunoblot analysis using rabbit anti-
CaMy1 (1:10,000) antibodies.2.8. Co-immunoprecipitation
HEK293 cells were double-transfected with 1 mg of each of the
plasmids: SCG10-Flag and green ﬂuorescent protein (GFP), or SCG10-
Flag and CaMy1-GFP. Twenty-four hours after transfection, cells were
lysed for 30 min at 4 °C in buffer A containing either 2 mM EGTA or
0.2 mMCaCl2 and centrifuged at 23,000×g. The resulting supernatants
containing 800 μg total proteinwere added to 30 μl anti-FlagM2 beads
(Sigma). After overnight incubation with the supernatants at 4 °C,
beads were washed three times with buffer A, and bound proteins
were eluted by adding SDS-PAGE sample buffer and heating for 3 min
at 95 °C. Proteins in the immunoprecipitates were separated by 12%
SDS-PAGE, transferred to a nitrocellulose membrane (Protran, What-
mann), and immunoblotted with the rabbit anti-GFP antibody
(1:5000, Abcam) or mouse anti-Flag M2 antibody (1:1000, Sigma).2.9. Immunolocalization and ﬂuorescence microscopy
For immunostaining, primary rat hippocampal cultures transfected
or not transfected with pEGFPN2CaMy1 and p3xFlagCMV14SCG10
were ﬁxed for 10 min with buffer B containing 4% PFA, 0.1%
glutaraldehyde, 3% sucrose, 50 mM PIPES, pH 6.8, 2 mM EGTA,
1 mM MgCl2, and 1 mM GTP for 30 min at 37 °C. After ﬁxation, cells
were washed with PBS for 15 min at room temperature and
incubatedwith the following primary antibodies in blocking solution
(10% horse serum, 2% BSA, 4% sucrose, and 0.2% Triton X-100 in PBS)
at 4 °C overnight: rabbit anti-CaMy1 (1:250), mouse anti-SCG10
(1:250, NeuroMab), rabbit anti-GFP (1:2000, Abcam), and mouse
anti-Flag M2 (1:500, Sigma). Cells were then washed three times in
PBS for 10 min at room temperature. Secondary antibodies were
applied in a blocking solution for 1.5 h at room temperature and
washed three times in PBS for 10 min. Secondary antibodies
conjugated with Alexa-ﬂuor 488 (1:500), Alexa-ﬂuor 568 (1:500),
and Alexa-ﬂuor 594 (1:500) and the nuclei marker Hoechst
(Invitrogen) were used for labeling (Molecular Probes).
For immunostaining, PC12 cells were ﬁxed for 10 min and stained
according to a previous protocol with primary antibodies (rabbit anti-
GFP, 1:1000, MBL; mouse anti-Flag M2, 1:500, Sigma; mouse anti-
SCG10, 1:250, NeuroMab) and secondary antibodies (Alexa-ﬂuor 488,
1:500; Alexa-ﬂuor 594, 1:500).
Confocal laser scanning images of immunostained primary hippo-
campal neurons, and PC12 cells were obtained with the sequential
acquisition settings at the maximal resolution (1024×1024 pixels) of a
Zeiss LSM 510 microscope. Images of differentiated PC12 cells were
obtained with an Eclipse 80i epiﬂuorescence microscope (Nikon). The
length of projections of PC12 cells wasmeasured using ImageJ software
supplemented with Sholl analysis and a NeuronJ plugin.
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The proximity ligation assay (PLA) was performed in HeLa cells
24 h after double-transfection with plasmids encoding SCG10-Flag,
SCG10d35-Flag, SCG10-GFP, CaMy1-Flag, CaMy1-GFP, and GFP. HeLa
cells transfectedwith CaMy1-GFP and SCG10-Flag were stimulated for
10 min with 5 μM BAPTA and 5 μM ionomycin dissolved in pre-
warmed DMEM. Cells were ﬁxed for 10 min with buffer B as described
above, washed with PBS at room temperature, blocked in blocking
solution for 30 min at room temperature, and incubated with the
following primary antibodies in the blocking solution at 4 °C
overnight: rabbit anti-GFP (1:4000, MBL), mouse anti-Flag (1:2000,
Sigma), and mouse anti-tubulin (1:4000, Sigma). The PLA assay was
further performed using the Duolink™ kit according to the manufac-
turer's instructions (http://www.olink.com; [41]). Confocal images of
cells were obtained with sequential acquisition settings (0.2–0.27 μm
Z-stack) at 63× magniﬁcation (Zeiss, Plan-Apochromat, 63×/11.40 Oil
DIC M27) and the maximal resolution (1024×1024 pixels) with an
LSM5 Exciter Zeiss microscope and ZEN2007 software (Carl Zeiss).
The PLA signal was analyzed using MetaMorph software (Visitron
Systems).
2.11. Tubulin polymerization assay
An in vitro tubulin polymerization assay was performed using a
BK011 Kit (Tebu Bio) in 96-well-plate format according to the
manufacturer's protocol. Fluorescently stained tubulin was mixed
with puriﬁed proteins (recombinant CaMy1, MBP, SCG10-MBP, or
SCG10-MBP combined with CaMy1). Prepared protein solutions were
heated from 4 °C to 37 °C and incubated for 1 h with tubulin. During
this time, an increasing ﬂuorescent signal of polymerizing tubulin was
recorded using a Synergy HT Multi Detection Micro Plate Reader
spectroﬂuorimeter (excitation λ 350 nm±20, emission λ 580±20,
signal acquisition every 30 s).
2.12. Other materials and procedures
Theprotein concentrationwasdetermined according to theBradford
method (Bio-Rad reagent) with BSA as a standard. SDS-PAGE (reducing
conditions) was performed on 4% stacking and 12% resolving gels. Gels
were stained with Coomassie brilliant blue (Bio-Rad). After SDS-PAGE,
the molecular mass of the proteins was determined using Gene Tool
software (Syngene). Statistical analyses were performed with PRISM
version 5.02 software (GraphPad, San Diego, CA, USA) using one-way
analysis of variance (ANOVA) followed by Tukey's multiple test. All
differences were considered signiﬁcant at a level of pb0.05.
3. Results
3.1. CaMy1 binds human brain SCG10
To identify the binding partners of CaMy1 in the developing
human brain, we performed a yeast two-hybrid screen of a fetal
human brain cDNA library using full-length CaMy1 as bait. A screen of
7×106 diploidal cotransformants led to the isolation of 1000 clones, of
which 170 prey plasmids were retested for their positive phenotype.
In seven independent clones that grew on selective medium andwere
β-galactosidase-positive, the prey vectors contained a full coding
sequence of SCG10 protein. The full coding sequence of SCG10 from
one of the isolated sequences was cloned into the prey vector and
retested against CaMy1, conﬁrming the CaMy1/SCG10 two-hybrid
interaction (see Supplementary materials, Fig. S1). In the control
experiment, the coding sequence of homologous stathmin1 was
cloned into a prey vector and tested in the samemanner as the SCG10
construct. In contrast to SCG10, stathmin1 did not yield a positive
yeast two-hybrid reaction with CaMy1.The interaction between CaMy1 and SCG10 in the yeast two-
hybrid system was also observed when the experimental system was
inverted, in which SCG10 was cloned into a bait vector and CaMy1
into a prey vector. The above results demonstrate that CaMy1
interacts with SCG10 protein (stathmin2), whereas CaMy1 does not
bind to the SCG10 homolog stathmin1.
3.2. CaMy1 and SCG10 protein levels increase during early neural
development
To assess the possibility that the CaMy1/SCG10 interaction occurs
during neuronal development, we determined and compared the
developmental patterns of CaMy1 and SCG10 mRNA and protein levels
in primary rat cortical neurons cultured from day 1 to day 21 (1DIV–
21DIV). Quantitative real-time PCR analysis revealed a gradual increase
in CaMy1 transcript levels during neuronal development up to 14DIV.
CaMy1mRNA levels remained relatively stable later in culture (Fig. 1A).
In developing neurons, SCG10 mRNA levels increased similarly to
CaMy1 (i.e., from 3DIV to 14DIV; Fig. 1A). After 14DIV, the SCG10
transcript level decreased by 21DIV, which was consistent with the
previously described downregulation of SCG10 upon maturation
[30,42]. As a control, we also analyzed the expression pattern of the
doublecortin protein known to progressively decrease during the entire
neuronal developmental period [43,44].
Immunoblotting with anti-CaMy1 antibodies revealed endoge-
nous CaMy1 protein in rat embryo cortex lysate and in early
developing neurons (Fig. 1B). CaMy1 protein levels increased during
the ﬁrst week of neuron development in culture, corresponding to
CaMy1 mRNA levels. In contrast to mRNA, CaMy1 protein levels
decreased when the cells approached maturity (Fig. 1B). Because
protein levels can be regulated by posttranslational mechanisms,
mRNA expression patterns, and protein level patterns, they are
sometimes not identical. These results indicate that during later stages
of differentiation, CaMy1 protein levels in neurons are subjected to
additional regulation, possibly by mechanisms related to protein
degradation or stability, while transcription is still active. Importantly,
the pattern of CaMy1 protein levels was similar to the pattern of
SCG10 protein levels — both proteins increased earlier in develop-
ment and decreased during the later stages (Fig. 1B). The demon-
strated upregulation of both the CaMy1 and SCG10 proteins during
the early stages of neuronal culture indicates no temporal limitations
of the interaction between these two proteins during early neuronal
development.
3.3. CaMy1 co-localizes with SCG10 in developing primary rat
hippocampal neurons and PC12 cells
We then studied the subcellular localization of CaMy1 and SCG10
proteins in early differentiating (7DIV) primary rat hippocampal
neurons using confocal microscopy. Doubly immunostained neurons
with the speciﬁc anti-CaMy1 and anti-SCG10 antibodies showed that
endogenous CaMy1 and SCG10 are similarly spread in the perinuclear
region of the cytoplasm and primary neurites (Fig. 2A). Co-localization
of both proteins in the perinuclear region of developing neurons is
clearly visible (Fig. 2A). SCG10 is targeted to growth cones where it
regulates dynamic reorganization ofmicrotubule cytoskeleton, andwe
sought to determine whether CaMy1 is also transported to the growth
cones. Therefore, we transfected primary hippocampal neurons with
SCG10-Flag and CaMy1-GFP and assessed the subcellular localization
of these proteins using confocal microscopy. CaMy1-GFP protein was
detected not only in the cell body and neuritis (Fig. 2B, left panel), but
also in some growth cones where its colocalization with SCG10-Flag
was visible (Fig. 2B, right panel).
Additionally, we employed PC12 cells as a model widely used in
deciphering the mechanisms of neuritogenesis. PC12 cells are known
to express endogenous SCG10 upon stimulation with NGF [45].
Fig. 1. CaMy1mRNA and protein levels are developmentally regulated in primary cultured cortical neurons from embryonic rat brains. Rat cortical neurons obtained from embryonic
day 19 (E19) rat brains were cultured for 21 days. (A) Total RNA was isolated from neurons at different days in culture. CaMy1, SCG10, and doublecortin (DCX) mRNA levels relative
to 18S mRNA were calculated from three independent experiments and are expressed as mean±SEM. CaMy1 mRNA levels gradually increased up to 14 days in culture (14DIV),
similar to SCG10 transcript levels. DCX mRNA levels consistently decreased during neuronal development. (B) Protein levels of CaMy1 and SCG10 in E19 rat cortex (Embryo) and
during the development of rat cortical neurons in culture were analyzed by immunoblotting with anti-CaMy1 and anti-SCG10 antibodies and compared with GAPDH levels using
densitometry. CaMy1 and SCG10 protein levels increased during early neuronal development and decreased during the later stages of differentiation. The data presented here are
from a single analysis that is representative of three independent experiments in which both proteins were analyzed simultaneously. Black bars, CaMy1; gray bars, SCG10.
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mRNA levels in NGF-treated or -untreated PC12 cells, we transfected
these cells with CaMy1-GFP. After 3 days of differentiation upon NGF
treatment, we analyzed the colocalization of endogenous SCG10 and
overexpressed CaMy1-GFP using immunocytochemistry with anti-
bodies against SCG10 and GFP (Fig. 2C). The confocal images revealed
colocalization of CaMy1 and SCG10 in the neurite tips at the end of
developing neurites of PC12 cells.
The co-localization of CaMy1with SCG10 in the neuronal cell body,
neurites, and growth cones suggests that the CaMy1/SCG10 interac-
tion may play a physiological role in developing neurons.
3.4. CaMy1 interaction with SCG10 is Ca2+-dependent in vitro and
in vivo
CaMy1 is known to bind Ca2+, and we analyzed whether the
interaction between CaMy1 and SCG10 depends on Ca2+ concentra-
tion [Ca2+]. We ﬁrst addressed this question using pull-down
experiments with immobilized recombinant SCG10 and puriﬁed
recombinant CaMy1 or endogenous CaMy1 present in cell lysates.
Recombinant CaMy1 protein after tag removal was incubated with
Amylosepharose resin with immobilized SCG10-MBP or MBP as a
control (Fig. 3A, upper panel). Immunoblotting of the bound fraction
showed that recombinant CaMy1 was retarded on the SCG10-resinonly in the buffer containing the Ca2+ chelator EGTA and not in the
presence of 0.2 mM Ca2+. In the control experiments, CaMy1 did not
bind to MBP-tag alone. These data conﬁrm the direct interaction
between CaMy1 and SCG10 and indicate its dependence on Ca2+
concentration. Similarly, endogenous CaMy1 from lymphocyte lysates
was pulled down using SCG10-MBP resin (and not by control MBP)
only in the presence of 2 mM EGTA but not in the presence of 0.2 mM
Ca2+ (Fig. 3A, lower panel).
The above results demonstrated that CaMy1 associates with SCG10
in a Ca2+-dependent manner, and we next analyzed the interaction
between recombinant CaMy1 and SCG10 in the step gradient of
increasing [Ca2+] ranging from 0.1 to 50 μM.With the constant amount
of CaMy1 and SCG10 proteins in the input, the highest amount of the
pulled-down CaMy1 was observed with a low [Ca2+], up to 10 μM. At
20 μM Ca2+, the amount of bound CaMy1 was already reduced
compared with the amount of CaMy1 bound in the presence of EGTA
and gradually decreased in [Ca2+] greater than 20 μM (Fig. 3B).
Ca2+-regulated binding of CaMy1 with SCG10 was further
conﬁrmed using a co-immunoprecipitation assay from HEK293 cells
transiently transfected with Flag-tagged SCG10 and CaMy1-GFP
(Fig. 3C). As shown on the immunoblots, from the immunoprecipi-
tates obtained with anti-GFP antibodies, anti-Flag antibodies co-
immunoprecipitated SCG10-Flag with CaMy1-GFP when cell extracts
contained 2 mM EGTA but not in the presence of 0.2 mM Ca2+
Fig. 2. CaMy1 co-localizes with SCG10 in developing hippocampal neurons and in differentiating PC12 cells. (A) Primary hippocampal neurons prepared from embryonic day 19 rat
brains were stained for endogenous CaMy1 (rabbit anti-CaMy1 antibody, Alexa 488, green) and SCG10 (mouse anti-SCG10, Alexa 594, red) on day 7 in culture (7DIV). CaMy1 and
SCG10 immunoreactivity, analyzed by confocal microscopy, was colocalized in the perinuclear region (yellow areas). Scale bar=20 μm. The inset shows a magniﬁed fragment of the
perinuclear region. Colocalization of CaMy1 and SCG10 signals (yellow) is indicated by the arrows. (B) CaMy1-GFP and SCG10-Flag were overexpressed in primary cultured
hippocampal neurons (6–9DIV). Cells were labeled with antibodies against SCG10-Flag (mouse anti-Flag, Alexa 568, red). (Left panel) Maximal projection of entire neuron with
marked growth cone position. Scale bar=50 μm. (Right panel) Magniﬁcation of the neuronal growth cone demonstrates colocalization of CaMy1 signals (green) with SCG10 signals
(red). Arrows indicate colocalization sites of both signals visible as yellow dots. Z-stack, scale bar=1 μm. (C) PC12 cells were transfected with CaMy1-GFP and stimulated by NGF for
differentiation (75 ng/ml). Cells were stained for endogenous SCG10 (mouse anti-SCG10, Alexa 594, red). Arrows indicate colocalization sites of both signals (yellow areas). CaMy1-
GFP colocalized with endogenous SCG10 in proximity to neurite tips. Scale bar=20 μm.
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in high or low [Ca2+] (Fig. 3D).
To directly visualize Ca2+-dependent CaMy1/SCG10 interaction in
cells, we applied the recently established PLA. Thismethod is based on
the simultaneous and proximate recognition of interacting protein
molecules by pairs of antibodies linked to oligonucleotides. DNA
strands arising upon ampliﬁcation of ligated oligonucleotides serve as
markers of protein complexes and can be analyzed by confocal
microscopy. Studies using PLA were performed in HeLa cells
characterized by intensive reorganization of the MT cytoskeleton in
the leading edge of lamellipodia, which are similar to neuronal growth
cones. Because lamellipodia are much larger than growth cones, this
model is often used for investigations of MT regulation.
As shown in Fig. 4A and B, SCG10-GFP alone was spread
throughout the entire cytoplasm and was additionally concentrated
in areas inside the cells that likely correspond to the Golgi apparatus
where SCG10 is known to accumulate for transport to the cell
periphery [30,46]. Using PLA, we ﬁrst demonstrated the SCG10/
tubulin interaction in HeLa cells that overexpress SCG10-GFP,
conﬁrming the known ability of SCG10 to bind tubulin (Fig. 4A, left
panel). The PLA signals that revealed the SCG10/tubulin interaction
were located mainly in subcellular areas in close proximity to the
leading edge of lamellipodia where intense reorganization of micro-
tubules occurs. In contrast, control PLA using anti-GFP and anti-tubulin antibodies in cells that overexpressed GFP alone did not result
in a signiﬁcant number of PLA signals (Fig. 4A, right panel).
We next analyzed the SCG10 and CaMy1 interaction in either HeLa
cells cotransfected with SCG10-GFP and CaMy1-Flag (Fig. 4B, left
panel) or in cells cotransfected with SCG10-Flag and CaMy1-GFP
(Fig. 4B, right panel). CaMy1-GFP alone was spread throughout the
cytoplasm, whereas the PLA signals of the CaMy1/SCG10 complexes in
both experimental settings were located in subcellular areas, similar
to the signals of SCG10/tubulin, which were in close proximity to the
leading edge of lamellipodia (compare PLA in Fig. 4A and B). The
similar localization of CaMy1/SCG10 and SCG10/tubulin complexes
suggested the involvement of CaMy1 in the SCG10-mediated
regulation of MT reorganization at the edge of lamellipodia.
The PLA-demonstrated interaction between CaMy1 and SCG10
proteins occurred in non-activated cells where the Ca2+ concentra-
tion is low (average ~100 nM). This is consistent with the results of
our pull-down experiments, in which CaMy1 was shown to associate
with SCG10 at low [Ca2+] below 200 nM. To further study the
inﬂuence of cytoplasmic [Ca2+] on the CaMy1/SCG10 interaction, we
performed PLA in HeLa cells treated with agents that regulate
intracellular Ca2+ levels (Fig. 4C). Upon triggering an increase in
intracellular Ca2+ levels by treatment with ionomycin, the PLA signals
of the CaMy1/SCG10 complexes were signiﬁcantly diminished
compared with DMSO-treated control cells. Quantiﬁcation of PLA
Fig. 3. CaMy1 interacts with SCG10 in a Ca2+-dependent manner in vitro. (A) Puriﬁed
recombinant CaMy1 (upperpanel) and lymphocyte lysates containingendogenousCaMy1
were incubatedwith SCG10-MBPorMBP immobilizedonAmyloseResin in thepresenceof
2 mM EGTA or 0.2 mM CaCl2. Pull-down fractions were analyzed by Western blot (WB)
using an anti-CaMy1 antibody. SCG10 pulled down CaMy1 in the presence of EGTA,
whereas no interaction was observed at 0.2 mM CaCl2. (B) Recombinant CaMy1 was
incubated with SCG10-MBP Amylose Resin in the presence of 2 mM EGTA or Ca2+ at
concentrations ranging from0.1 to 50 μM.Pull-down fractionswere analyzedbyWBusing
an anti-CaMy1 antibody. (C, D) SCG10-Flag and CaMy1-GFP or GFP alone were
overexpressed in HEK293 cells and co-immunoprecipitated (IP) with anti-Flag antibody
in 2 mM EGTA or 0.2 mM CaCl2. Immunoprecipitates were analyzed byWBwith anti-Flag
or anti-GFP antibodies. CaMy1-GFP co-immunoprecipitated with SCG10-Flag only in the
presence of EGTA (C), whereas in the control experiment, GFP alone was not
immunoprecipitatedwith SCG10-Flag (D). I, input; U, unbound fraction;W,wash fraction;
Pd, pull-down fraction; IP, co-immunoprecipitation fraction.
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complexes by approximately 40% (pb0.05). In contrast, a decrease in
cytoplasmic [Ca2+] by BAPTA treatment resulted in a noticeable but
nonsigniﬁcant increase in PLA signals for the CaMy1/SCG10 com-
plexes (Fig. 4C). In summary, the PLA results revealed CaMy1/SCG10
complexes at resting cellular conditions when [Ca2+] was low and
conﬁrmed a dissociation of these complexes upon an increase in
cytoplasmic [Ca2+]. CaMy1/SCG10 complexes were found in lamelli-
podia of HeLa cells where SCG10 regulates MTs.3.5. CaMy1/SCG10 binding involves CaMy1 C-terminal domain and
N-terminal SCG10 fragment
As shown schematically in Fig. 5A, a CaMy1 N-terminal fragment
(residues 1–98) contains two nonfunctional EF-hands, EF-1 and EF-2,
and is responsible for membrane anchoring of CaMy1 attributable to
myristoylated cysteine at the second amino acid position, whereas the
C-terminal half of CaMy1 (residues 99–192) contains two functional
EF-hands, EF-3 and EF-4, and is responsible for Ca2+ binding (Fig. 5A)
[7]. To elucidate which part of CaMy1 binds to SCG10, we establishedthree peptide fragments of CaMy1 fused to a GST tag: CaMy1NTF
containing N-terminal EF-1 and EF-2, CaMy1CTF containing EF-3
and EF-4, and CaMy1MDF containing nonactive EF-2 and Ca2+-binding
EF-3 motifs. CaMy1NTF and CaMy1CTF were efﬁciently expressed in
E. coli, puriﬁed, and applied in the pull-down experiments with
immobilized SCG10. CaMy1MDF was unstable, and its puriﬁcation was
not possible. In the pull-down experiments, CaMy1NTF exhibited
no retardation of SCG10 resin either at a high or low Ca2+ condition,
whereas CaMy1CTF binding was observed in the buffer containing
2 mM EGTA but not in the presence of 0.2 mM CaCl2, which was
similar to the entire protein (Fig. 5B).
We then sought to localize the CaMy1 binding site in SCG10
protein. As shown in Fig. 5C, SCG10 has three functional regions,
an N-terminal membrane-anchoring domain, a central regulatory
domain, and a C-terminal coiled-coil domain common for all
stathmins and responsible for tubulin binding [30]. The N-terminal
35 amino acid long domain harbors palmitoylation sites that anchor
SCG10 Golgi-derived vesicles which transport SCG10 to neuronal
growth cones. The regulatory domain contains phosphorylation
sites for kinases that negatively regulate the MT-destabilizing
activity of SCG10 [47].
In the yeast two-hybrid experiment, we found that CaMy1
strongly interacted with SCG10 but did not interact with stathmin1,
which lacks the N-terminal domain present in SCG10 (Fig. 5C). These
results suggest that the N-terminal fragment of SCG10 might be
crucial for CaMy1 binding. To conﬁrm this assumption, we expressed
in E. coli an MBP-tagged SCG10 lacking its N-terminal domain
(SCG10d35-MBP). SCG10d35-MBP resin did not pull down recombi-
nant CaMy1 either in EGTA or in 0.2 mM Ca2+ (Fig. 5D).
We further conﬁrmed the crucial role of the N-terminal SCG10
fragment in CaMy1 binding using PLA (Fig. 5E). HeLa cells were co-
transfected with CaMy1-GFP and SCG10d35-Flag or SCG10-Flag for
control, and the protein–protein interactions were examined with anti-
GFP and anti-Flag antibodies, followedby a PLA reaction. In control cells,
CaMy1/SCG10 complexes were visible as PLA dots located in lamelli-
podia at the cell edges, whereas almost no PLA signals were observed in
cells co-expressing CaMy1 and SCG10d35 (Fig. 5E). The results of the
PLA tests, pull-downs, and yeast two-hybrid experiments are consistent
and point to the N-terminal 35 amino acid domain in SCG10 as a region
that is crucial for CaMy1 binding.
3.6. CaMy1 inhibits the negative effect of SCG10 on tubulin polymerization
Because the N-terminal domain of SCG10 involved in the
interaction with CaMy1 is not required for the binding with αβ-
tubulin dimers [31,42], our results suggest that CaMy1 does not
compete with tubulin for the SCG10 binding site. However, CaMy1
binding to SCG10 might modulate the MT-destabilizing activity of the
C-terminal, stathmin-like domain (SLD) in SCG10. To verify this
hypothesis, we ﬁrst evaluated the effect of CaMy1 on SCG10 activity in
the tubulin polymerization assay in vitro (Fig. 6). In this assay,
recombinant CaMy1 and SCG10 proteins were used. Because of the
low stability of SCG10 after proteolytic removal of the MBP tag,
SCG10-MBP fusion protein was applied. In the control experiments,
temperature elevation in the solution of soluble, ﬂuorescently labeled
tubulin from 4 °C to 37 °C led to tubulin polymerization, detected as
an increase in the ﬂuorescent signal. As expected, the addition of
control MBP to soluble tubulin had no effect on polymerization. In
contrast, 2.5 μM or 5 μM SCG10-MBP signiﬁcantly and dose-depen-
dently decreased the amount of polymerized MTs, reﬂected by a
lowering of the ﬂuorescence plateau (Fig. 6, left upper panel). When
these results were expressed as relative ﬂuorescence intensity at the
60th minute of the experiment, the amounts of MTs were reduced by
50% and nearly 70%, respectively (Fig. 6, right upper panel). CaMy1
(5 μM) alone or CaMy1 and MBP at concentrations of 2.5 μM and 5 μM
had no signiﬁcant effect on tubulin polymerization (Fig. 6, left lower
Fig. 4. Formation of CaMy1/SCG10 complexes in HeLa cells is Ca2+-dependent. (A) HeLa cells were transiently transfectedwith SCG10-GFP (left panel) or GFP (right panel). A signiﬁcant
number of PLA signals were obtained with anti-GFP and anti-tubulin antibodies only in SCG10-GFP-transfected cells, indicating the formation of SCG10/tubulin complexes. SCG10 was
associatedwith tubulin in lamellipodia and distal regions of the cytoplasm. (B) HeLa cells were transiently co-transfectedwith SCG10-GFP and CaMy1-Flag (left panel) or SCG10-Flag and
CaMy1-GFP (rightpanel). PLA signals obtainedwith anti-Flag and anti-GFP antibodies demonstrated localizationof CaMy1/SCG10 complexesmainly in lamellipodia inboth cases. (C)HeLa
cells were transiently transfected with CaMy1-GFP and SCG10-Flag, treated with DMSO (control), ionophore ionomycin (5 μM), or Ca2+-chelator BAPTA, and ﬁxed. (Left panel) Protein
interactions were visualized by PLA using anti-Flag and anti-GFP antibodies and analyzed by confocal microscopy. (Right panel) The number of PLA signals per cell from the three
independent experiments is expressed as themean±SEM(errorbar). ⁎pb0.05. Ionomycin treatment increased cytoplasmic [Ca2+] and resulted in a signiﬁcant reductionof CaMy1/SCG10
complexes, whereas BAPTA decreased cytoplasmic [Ca2+] and enhanced the number of CaMy1/SCG10 complexes.
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containing 2.5 μM SCG10 resulted in an elevation of the relative
ﬂuorescence of polymerized MTs from 52% to 69% (pb0.01; Fig. 6,
right lower panel). These results suggest that CaMy1 binding to SCG10
can block the sequestration ofαβ-tubulin by SCG10 and consequently
elevate the amount of free αβ-tubulin heterodimers available for
polymerization.
3.7. CaMy1 inhibits differentiation of NGF-stimulated PC12 cells
We then studied the physiological function of CaMy1 in neurite
outgrowth by employing a PC12 cell model. As described above(Fig. 2C), overexpressed CaMy1 colocalized with endogenous
SCG10 in proximity of growth cone-like structures at the end of
developing neurites of PC12 cells. We next investigated whether
CaMy1 overexpression has any consequences on NGF-induced
neurite elongation in PC12 cells. Neurite lengths and number were
measured and compared in single-transfected cells transiently over-
expressing SCG10-Flag or SCG10d35-Flag (N-terminal SCG10 mutant
defective in binding to the Golgi-derived vesicles targeting SCG10 to
growth cones) and in double-transfectants additionally overexpres-
sing CaMy1-GFP (Fig. 7). Expression of CaMy1 alone signiﬁcantly
reduced neurite lengths and number that can be explained by the
inhibition of endogenous SCG10 known to be present in these cells.
Fig. 5. CaMy1CTF andSCG10NTF are required for CaMy1/SCG10 interaction. (A) Schematic representation of CaMy1 protein and its deletionmutants. The CaMy1CTF domain (residues 99–
192) contains the EF-3 and EF-4 motifs responsible for Ca2+ binding. The CaMy1NTF domain (residues 1–98) contains non-functional EF-hands (EF-1 and EF-2) and a myristoylation site.
(B) CaMy1,CaMy1CTF-GST, andCaMy1NTF-GSTwere applied on SCG10-MBPbound toAmyloseResin at 0.2 mMCa2+or2 mMEGTA.CaMy1CTF showedan interactionwith SCG10-MBP in
thepresenceof 2 mMEGTA,whereas no interactionwas observed for CaMy1NTF. (C) Schematic structures of SCG10, SCG10deletionmutant lacking 35N-terminal amino acid residues, and
stathmin1. Arrows indicate phosphorylation sites. Black pentagon points indicate two cysteine residues that are sites for palmitoylation. (D) Recombinant CaMy1was applied on the resin
with immobilizedSCG10d35-MBPorSCG10-MBP. In contrast to SCG10, SCG10d35didnot pull downCaMy1at either a loworhighCa2+concentration. (E)HeLa cellswere transfectedwith
CaMy1-GFP and SCG10-Flag (positive control) or SCG10d35-Flag and further subjected to PLA. The large number of PLA signals (red dots) indicates the presence of complexes in
lamellipodia and inproximity to the cellmembrane (left panel). In the cells expressing CaMy1-GFPwith truncated SCG10d35-Flag, only fewPLA dots per cell are detectable, indicating that
the interaction did not occur (right panel). Scale bars=10 μm left panel, 2 μm right panel.
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neurite outgrowth parameters compared with wildtype SCG10. The
data reveal that SCG10d35 mutant, which contains tubulin binding
domain, exhibits some activities towards microtubules and affects the
activity and/or level of endogenous SCG10. Coexpression of CaMy1 in
SCG10-transfected cells resulted in a signiﬁcant decrease in the
neurite outgrowth parameters, such as number and length of neurite
projections and neurite tips. In contrast, CaMy1 overexpression did
not change neurite outgrowth in cells coexpressing an N-terminal
SCG10d35 mutant unable to bind CaMy1. These data indicate that
exogenous CaMy1 inhibited SCG10 in PC12 cells, causing a signiﬁcant
reduction in neurite outgrowth. The results further indicate that
CaMy1 can function as a regulator of MT dynamics in neurite
outgrowth.
4. Discussion
This is the ﬁrst report of which we are aware showing that CaMy1
can modulate neurite outgrowth by its Ca2+-dependent interaction
with MT dynamics-regulator SCG10. We found that CaMy1 mRNA and
protein levels are present in the embryo and are upregulated in
developing rat cortical neurons similarly to SCG10 levels; both proteinsdecrease upon maturity. Moreover, CaMy1 and SCG10 were co-
immunolocalized in cell soma, dendrites, and neuronal growth cones
in developing primary neurons and in PC12 cells differentiating upon
NGF treatment. The CaMy1 interactionwith SCG10was revealed by the
yeast two-hybrid screen of a fetal human brain library. The Ca2+-
dependence of this interactionwasproven in vitro and in vivousingpull-
down, co-immunoprecipitation, and PLA assays. Ca2+-regulated forma-
tion of CaMy1/SCG10 complexes in transfected HeLa cells was observed
predominantly in lamellipodia (i.e., at the sites of MT end reorganiza-
tion). The potential role of CaMy1 in SCG10 activity inMTdynamicswas
further supported by the demonstration that CaMy1 disrupts the MT
depolymerization activity of SCG10 in vitro and that CaMy1 over-
expression attenuates SCG10-related neurite outgrowth in PC12 cells
stimulated with NGF.
For over 10 years, CaMy1 has been suggested to play a role in the
regulation of neuronal function, and some of the putative CaMy1
neuronal protein partners have been identiﬁed. For example, CaMy1
was identiﬁed as a binding partner of Alzheimer's disease-associated
presenilin 2 (PS2) [11]. However, in contrast to the original
hypothesis, we demonstrated that the transmission of Ca2+ signals
to PS2 in neurons by CaMy1 is unlikely because of the very limited
cellular and subcellular colocalization of the two proteins [18]. Other
Fig. 6. CaMy1modulates SCG10 inhibitory effect onmicrotubule assembly in vitro. (Upper panel) Polymerization of ﬂuorescently labeled tubulin wasmonitored either in the absence
(control) or following the addition of MBP or SCG10-MBP. The data in the left graph were derived from an experiment that was typical of four experiments, for which mean values
are shown on the right graph. As expected, the addition of 2.5 μM or 5 μM SCG10-MBP decreased the ﬁnal amount of microtubules by over 50% and 70%, respectively. (Left lower
panel) Tubulin polymerization was measured in the absence (Ctrl) or presence of MBP, CaMy1, or both and is indicated on the graph. Neither CaMy1 nor MBP had any effect on
microtubule polymerization. (Right lower panel) Tubulin polymerization was measured in the presence of 2.5 μM SCG10-MBP alone or after the addition of 5 μM CaMy1. CaMy1
signiﬁcantly elevated microtubule assemblies from 52% to 69%. Each bar represents the average of four independent experiments±SEM. ⁎⁎⁎pb0.001, ⁎⁎pb0.01 (ANOVA).
Fig. 7. CaMy1 inhibits differentiation of PC12 cells. PC12 cells were single transfected with GFP, CaMy1-GFP, SCG10-Flag, N-terminal mutant SCG10d35-Flag or co-transfected with
CaMy1-GFP and SCG10-Flag or SCG10d35-Flag. Subsequently, cells were stimulated to differentiation with 75 ng/ml NGF and analyzed after 5 days of PC12 cell differentiation.
(A) Microscopic images of cells. (B) Sholl analysis of neurite arbor (left panel), number of secondary extensions (middle panel), and number of neurite tips (right panel). The data are
expressed as mean±SEM (ANOVA) from ﬁve independent counts of 30–50 cells. CaMy1 signiﬁcantly decreased the number of neurites, shortened the length of neurite projections
in cells overexpressing SCG10, and did not affect neurite outgrowth in cells overexpressing SCG10d35. ⁎⁎⁎pb0.001, ⁎⁎pb0.01, ⁎pb0.05.
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cycle-associated kinases, which appeared to be involved in the
stabilization of long-term synaptic plasticity [12,48,49]. Among
the identiﬁed neuronal CaMy1 ligands are proteins known to func-
tion in neurogenesis and brain development, such as NBR1 and PAX3
[20–23]. The developmentally regulated CaMy1 expression pattern
revealed here and the interaction between CaMy1 and neuron-
speciﬁc SCG10 (stathmin2), which plays a key role in the regulation of
dynamic assembly and disassembly of MTs in developing neurons,
conﬁrm the hypothesis that CaMy1 is a protein that functions in
neuronal development and links CaMy1 with the control of the MT
cytoskeleton in this process. Although the function of the CaMy1/
SCG10 interaction in MT dynamics was demonstrated in a PC12
cell model, which is widely used in analyses of SCG10's involvement
in the mechanisms of neuritogenesis, further research is required to
decipher the functional and mechanistic aspects of the CaMy1/SCG10
interaction in neurons.
During neuronal development, MT assembly and disassembly
dynamics underlie multiple processes, including neurite outgrowth
and branching and growth cone steering and forward movements
[50]. Ca2+ signals play a signiﬁcant role in governing these processes
and must be transmitted to the MT-destabilizing stathmin phospho-
proteins to ensure tight control of MT dynamics [51,52]. The MT-
destabilizing activity of stathmins was shown to be under the control
of several serine and threonine kinases, including calmodulin-kinase
II and IV (CaMKII and CaMKIV), which phosphorylate sites located in
the regulatory domain of stathmins [30,53,54]. For example, Ca2+
signals associated with the activation of voltage-gated Ca2+ channels
andmetabotropic glutamate receptor 1 were shown to be transmitted
to stathmin1 by calmodulin kinase II (CaMKII), which negatively
regulates the activity of stathmin1 by phosphorylation of Ser16 and
stabilizes dendritic MTs [55].
The MT-destabilizing activity of SCG10 is similarly known to be
negatively regulated by multiple phosphorylations [30,31,53]. SCG10
was shown to be phosphorylated in vivo bymitogen-activated kinases
of the c-junNH2-terminal kinase group (JNK) that are essential during
brain development [35,47]. However, unclear is how Ca2+ signals
are transmitted to SCG10. This question is especially important
with regard to SCG10 accumulation and function in neurite tips where
Ca2+ signals are known to have profound regulatory effects on neural
outgrowth andmediate a large proportion of growth conemovements
toward or away from the stimuli [36]. SCG10 can be phosphorylated
by CaMKII in vitro [56], but the physiological role of such phosphor-
ylation has not yet been demonstrated. Unlike stathmin1, SCG10 did
not mediate Ca2+- and CaMKII-dependent regulation of dendritic
development [55]. Our data indicate that CaMy1 represents trans-
mission other than a phosphorylation-dependent type of Ca2+ signal
transmission to SCG10, which is based on negative SCG10 regulation
by a direct protein–protein interaction. Similar regulation of SCG10
was found for GTP-ase Rnd1, which directly interacts with SCG10 and
enhances the MT-destabilizing activity of SCG10 in axon extension
[32]. According to our model, at low Ca2+ levels in developing
neurites, CaMy1 binds SCG10 and inhibits its destabilizing effect on
MTs, whereas Ca2+ signals in the form of local or global [Ca2+]
elevations release SCG10 from complexes with CaMy1, resulting in
SCG10 activity toward MTs.
The transduction of Ca2+ signals to cellular effectors by EF-hand
proteins may be mediated by several mechanisms. According to the
classic paradigm, Ca2+ binding induces a conformational change in
an EF-hand protein, resulting in the formation of a hydrophobic
pocket at the sensor surface that enables target interactions.
Additionally, some Ca2+-binding EF-hand proteins interact with
their ligands also in low [Ca2+] (e.g., CaMy1). Platelet integrinαIIbβ3
and a member of the myosin-I family myo1 proteins bound to
CaMy1 in the presence of either Ca2+ chelator EGTA or in 100 nM
Ca2+, but their binding in higher [Ca2+] was enhanced [57]. Theinteraction between CaMy1 and SCG10 reported here occurred only
in low [Ca2+] in the presence of EGTA, thus showing inverse Ca2+-
dependence. This type of inverse Ca2+-regulated interaction was
not yet reported for CaMy1 and suggests that Ca2+-free CaMy1 has
different protein ligands and different functions from Ca2+-CaMy1.
This hypothesis is further supported by structural studies, in which
CaMy1 was shown to exist in multiple structural and metal ion-
bound states in vivo [9,58,59]. Speciﬁcally, CaMy1 binds one Mg2+
in the EF-3 motif, with a Kd near 120 μM, suggesting that in the
resting cell when [Ca2+] is low and [Mg2+] is in the millimolar
range, CaMy1 can exist as Mg2+-CaMy1. Further analyses are
required to compare the interaction between SCG10 and metal-
free apo-CaMy1 and Mg2+-CaMy1.
In the present study, we localized SCG10 binding in the C-terminal
CaMy1 domain because the N-terminal part of CaMy1 containing
the EF-1 and EF-2 motifs was not retained on SCG10 resin, whereas
the C-terminal fragment comprising EF-3 and EF-4 was able to bind
SCG10 in a Ca2+-dependent manner, similar to the observations with
wildtype CaMy1. This result is consistent with nuclear magnetic
resonance data for platelet integrin αIIbβ3, which revealed its binding
to a hydrophobic cleft localized mainly in the C-terminal domain of
CaMy1 in the vicinity of EF-3 and EF-4 [57–59].
The pull-down and PLA showed that CaMy1 binding requires the
N-terminal 35 amino acid long domain of SCG10 protein. CaMy1
binding in the N-terminal fragment of SCG10 appears to sterically
block the binding site for the ﬁrst αβ-tubulin heterodimer, which is
known to be located close to the N-terminal fragment and the
adjacent regulatory domain, that may account for the CaMy1
inhibitory effect on SCG10 activity [60]. Notably, the N-terminal
domain responsible for CaMy1 binding is absent in stathmin1 but
present in other stathmin family protein members, such as SCG10-
like-protein (SCLIP, stathmin3), stathmin-like-protein RB3 (stath-
min4), and its two isoforms, with 70% sequence homology for SCLIP
and 57% for RB3. The conserved N-terminal domain contains two
cysteine palmitoylation sites and is responsible for the Golgi and
vesicle-like localization of stathmin-related proteins and their growth
cone targeting, in contrast to cytosolic stathmin1 [61]. Despite their
similar subcellular localization, proteins in the stathmin family
containing the N-terminal domain fulﬁll at least partially distinct
biological roles during neuronal differentiation [62]. CaMy1 in our
studies did not signiﬁcantly change the targeting of SCG10 to neurite
tips, and whether CaMy1 can interact and modulate the localization
and function of other stathmins containing the conserved N-terminal
domain remains to be established.
SCG10 expression and metabolism have been suggested to be
altered in Alzheimer's disease and Down syndrome [63]. Similarly,
CaMy1 was implicated in Alzheimer's disease pathogenesis based on
our studies that indicated a substantial loss of CaMy1-immunoposi-
tive neurons and changes in intraneuronal CaMy1 localization in the
brains of Alzheimer's disease patients [17]. Therefore, an impaired
CaMy1/SCG10 interaction and the resulting impaired Ca2+ signaling
to the MT cytoskeleton may contribute to the neurodegeneration
process in Alzheimer's disease.
Altogether, the CaMy1/SCG10 interaction revealed in the present
study represents a possible mechanism that contributes to the Ca2+
signaling-dependent regulation of MT dynamics during neuronal
development. This is the ﬁrst report on a Ca2+-binding EF-hand
protein that directly binds and negatively modulates the function of a
stathmin family member.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbamcr.2010.12.023.
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